Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Lam Research
LRCX
|
$792M |
| 2 |
Johnson & Johnson
JNJ
|
$659M |
| 3 |
Datadog
DDOG
|
$571M |
| 4 |
Amazon
AMZN
|
$474M |
| 5 |
Broadcom
AVGO
|
$458M |
Top Sells
| 1 |
Workday
WDAY
|
$1.23B |
| 2 |
AbbVie
ABBV
|
$1.03B |
| 3 |
Advanced Micro Devices
AMD
|
$686M |
| 4 |
Honeywell
HON
|
$673M |
| 5 |
Amgen
AMGN
|
$620M |
Sector Composition
| 1 | Technology | 34.72% |
| 2 | Healthcare | 17.58% |
| 3 | Consumer Discretionary | 10.69% |
| 4 | Financials | 10.22% |
| 5 | Communication Services | 9.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
251
Ardelyx
ARDX
$1.57B
| $124M | 0.06% |
24,387,941
+2,858,061
| +13% | +$14.5M |
|
252
iShares Core S&P 500 ETF
IVV
$664B
| $123M | 0.06% |
+209,169
| New | +$123M |
|
253
Keysight
KEYS
$28.9B
| $122M | 0.06% |
761,527
-71,281
| -9% | -$11.5M |
|
254
EnerSys
ENS
$3.89B
| $122M | 0.06% |
1,322,767
+13,786
| +1% | +$1.27M |
|
255
Alight
ALIT
$2B
| $122M | 0.06% |
17,624,572
+229,466
| +1% | +$1.59M |
|
256
Gilead Sciences
GILD
$143B
| $120M | 0.06% |
1,296,077
-465,484
| -26% | -$43M |
|
257
Arcellx
ACLX
$4.03B
| $119M | 0.06% |
1,557,092
-454,858
| -23% | -$34.9M |
|
258
UL Solutions
ULS
$12.8B
| $119M | 0.06% |
2,389,077
+81,426
| +4% | +$4.06M |
|
259
Williams Companies
WMB
$69.9B
| $119M | 0.06% |
2,194,402
-1,274,424
| -37% | -$69M |
|
260
Doximity
DOCS
$13B
| $114M | 0.06% |
2,142,478
-322,409
| -13% | -$17.2M |
|
261
BellRing Brands
BRBR
$4.97B
| $114M | 0.06% |
1,514,623
-260,936
| -15% | -$19.7M |
|
262
Structure Therapeutics
GPCR
$1.27B
| $113M | 0.06% |
4,159,888
+203,010
| +5% | +$5.51M |
|
263
Xenon Pharmaceuticals
XENE
$3.02B
| $112M | 0.06% |
2,866,755
+314,363
| +12% | +$12.3M |
|
264
Nice
NICE
$8.67B
| $110M | 0.06% |
650,056
+5,609
| +0.9% | +$953K |
|
265
Xylem
XYL
$34.2B
| $109M | 0.06% |
938,055
-301,495
| -24% | -$35M |
|
266
Ligand Pharmaceuticals
LGND
$3.25B
| $109M | 0.06% |
1,015,023
+5,929
| +0.6% | +$635K |
|
267
Neurocrine Biosciences
NBIX
$14.3B
| $108M | 0.06% |
794,118
+1,922
| +0.2% | +$262K |
|
268
Arista Networks
ANET
$180B
| $107M | 0.05% |
971,547
-456,709
| -32% | -$50.5M |
|
269
Sotera Health
SHC
$4.44B
| $106M | 0.05% |
7,782,562
-4,886,228
| -39% | -$66.8M |
|
270
SPX Corp
SPXC
$9.28B
| $105M | 0.05% |
723,708
+26,995
| +4% | +$3.93M |
|
271
Inspire Medical Systems
INSP
$2.56B
| $105M | 0.05% |
567,312
+64,703
| +13% | +$12M |
|
272
PTC Therapeutics
PTCT
$4.55B
| $105M | 0.05% |
2,325,915
+455,698
| +24% | +$20.6M |
|
273
Marathon Petroleum
MPC
$54.8B
| $103M | 0.05% |
737,907
-35,291
| -5% | -$4.92M |
|
274
Paylocity
PCTY
$9.62B
| $103M | 0.05% |
514,471
-3,460
| -0.7% | -$690K |
|
275
NeoGenomics
NEO
$1.03B
| $102M | 0.05% |
6,165,063
-438,117
| -7% | -$7.22M |
|